Patents
Domantis granted broad European patent rights to pioneering half-life extension technology
Published in Gene Therapy Weekly, July 20th, 2006
AlbudAbs are dAbs that specifically bind to serum albumin and can dramatically enhance the half-life and efficacy of any molecule attached to them. The granted patent covers two or more dAbs linked to one another, where at least one dAb binds to serum albumin. The patent is the first to grant of a series of filings based on Domantis' pioneering AlbudAb approach. Domantis' lead AlbudAb program will enter late stage preclinical testing this year.
Dr. Ian Tomlinson, Domantis'...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-07-20)
More Articles from Gene Therapy Weekly
- Cancer Therapy
Proto-oncogene product directly controls cell cycle gene expression - Gene Transfer
Age-related vascular dysfunction lessened by extracellular superoxide dismutase - Neuroscience
Specific proteins are regulated in intact central nervous system - RNA Interference
Short interfering RNA mutation results in thermodynamically unstable duplex - West Nile Virus
West Nile virus replication inhibited using synthetic oligonucleotides - Allergy & Immunology
CD28 costimulation induces incomplete activation response in EBV-specific T cells - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
